TRODELVY® (sacituzumab govitecan-hziy) HCP Site

For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received 2 or more prior systemic therapies, at least one of them for metastatic disease1

A way in

with TRODELVY

TRODELVY attacks mTNBC with an antibody-drug conjugate (ADC) that binds to Trop-21

Based on preclinical data. May not
correlate with clinical outcomes.

PROVEN SURVIVAL BENEFIT
IN THE PHASE 3 ASCENT TRIAL

NEW INDICATION AS EARLY AS 2L
IN THE METASTATIC SETTING

for patients who have received 2 or more prior systemic therapies,
at least one of them for metastatic disease

*TRODELVY was studied in ASCENT, a phase 3, randomized, active-controlled, open-label trial. The efficacy analysis included Progression-Free Survival (PFS) in BM-neg patients (primary endpoint) by BICR based on RECIST 1.1 criteria, PFS for the full population (all patients with and without brain metastases), and Overall Survival (OS) vs single-agent chemotherapy.

  • 88% of the full population were BM-neg.1 Results in these patients were similar to those seen in the full population (all randomized patients).2 See full population data here
  • 13% of the full population in the TRODELVY group received only 1 prior line of systemic therapy in the metastatic setting (in addition to having disease recurrence or progression within 12 months of neoadjuvant/adjuvant systemic therapy). Efficacy results in this subgroup were consistent with those who received at least 2 prior lines in the metastatic setting1
BICR=blinded, independent, central review; CI=confidence interval; HR=hazard ratio; OS=Overall Survival; PFS=Progression-Free Survival; RECIST=Response Evaluation Criteria in Solid Tumors.
Trodelvy Access Support Logo

TRODELVY ACCESS SUPPORT can help you and your patients understand specific coverage and reimbursement guidelines for TRODELVY 180-mg single-dose vial. Call 1-844-TRODELVY (1-844-876-3358), Monday–Friday, 9 AM–7 PM ET.

Learn More

Download and complete the Patient Enrollment Form to get your patients started today

References: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021. 2. Data on file. Gilead Sciences, Inc. 2021.

Medical Information

For further information, please contact:
Phone: 1-888-983-4668 or Email: TRODELVY-MedInfo@gilead.com